To address a number of questions regarding the experimental use of bone marrow (BM) stem cells in hindlimb ischemia, including which is the best cell type (e.g., purified hematopoietic stem cell or monocytes), the best route of delivery [intramuscular (IM) or intravenous (IV)], and the mechanism of action (transdifferentiation or paracrine effects), we have compared the neovascularization capacities of CD133 + stem cells and monocytes (CD11b + ) from the BM of Tie2-GFP mice either via IV or IM in a murine severe hindlimb ischemia model. To test the effect of cytokine administration, an extra group received BM conditioned medium. Peripheral blood flow as well as capillary density and GPF-positivity detection in ischemic muscles was evaluated 7, 14, and 21 days postinjection. In addition, CD133 + and CD11b + cells from transgenic animals were cultured in vitro with angiogenic media for 7, 14, and 21 days to assess GFP expression. In all four cell-treated groups, blood flow and capillary density significantly recovered compared with the mice that received no cells or conditioned medium. There were no differences with respect to cell types or administration routes, with the exception of a faster flow recovery in the CD133 + -treated cell group. We did not find GFP + cells in the ischemic muscles and there was no GFP expression after in vitro proangiogenic culture. Our study shows that both purified CD133 + stem cells and myeloid mononuclear cells, either IM or IV administered, have similar neoangiogenic ability. Nevertheless, transdifferentiation into endothelial cells is not the mechanism responsible for their beneficial effect.
INTRODUCTION
Although prominin-1 function is not completely known, is coexpressed by both EPC and hematopoietic stem cells (HSC) and other tissue-specific stem cells, but not Evidence has accumulated over the past few years to suggest that bone marrow (BM) is a reservoir of cells by mature endothelial cells (34) . Several groups, including ours, have employed isolated human CD133 + cells with angiogenic properties, generally designated as endothelial progenitor cells (EPC) (12, 18, 29) . In a seminal for the treatment of myocardial (5, 37) or hindlimb ischemia (7). paper, Asahara and colleagues demonstrated for the first time in humans, the presence of circulating endothelial Because the definition and characterization of EPC is still controversial (16), some authors argue that the use progenitor cells, based on the expression of CD34 and Flk-1 (3) . Later, several groups showed that EPC also of selected populations may exclude important cell subsets with vasculogenic potential. For this reason, alterna-expressed the prominin-1 antigen (also called AC133 or CD133) (14, 27) . Mouse prominin-1 was initially isolated tive approaches based on cell therapy for ischemic diseases consist of delivering nonselected whole BM cells in 1997 from neuroepitelial stem cells and named for its location on the protrusion of cell membranes (42) .
or BM mononuclear cells (BM-MNC). BM or G-CSF mobilized peripheral blood (PB) MNC administration in location within the vascular endothelial surface and the coexpression of other endothelial-specific molecules experimental preclinical models has shown promising results, which has prompted the launch of clinical trials [e.g., endothelial nitric oxide synthase (eNOS)], it may be evidence that transdifferentiation is the main mecha-with nonselected MNC (6,21). However, a potential disadvantage of nonselected BM-MNC is the coadministra-nism of action controlling the vasculogenic effects of the transplanted BM cells. tion of several cell subsets with proinflammatory activity in an ischemic microenvironment, which could
In the present work, we have employed the Tie2-GFP murine model in order to address the aforementioned increase the risk of secondary effects (35, 44) . Monocytes, the main population contained in BM or PB questions concerning the preferable stem cell source, route of administration, and mechanism of action. MNC, have shown "in vitro" and "in vivo" vasculogenic potential (23, 30, 33, 40) . To avoid contamination with lymphocytes or other inflammatory cells, the administra-
MATERIALS AND METHODS tion of purified monocytes (CD14 + cells in humans or
An outline of all the experiments performed in this CD11b + cells in murine models) is therefore an attracstudy is depicted in Figure 1 . tive approach. Selected hematopoietic stem cells and monocyte administration has not been directly compared Mice to date. Few data are available from in vivo preclinical experiments (4), and none of them compared CD133 + Animal care and procedures were conducted in comcells with monocytes.
pliance with European and Spanish policies and all ex-There are at least two possible routes of administraperiments were approved by the Local Ethics Committion. Cells can be delivered directly by intramuscular tee. Wild-type FVB mice were obtained from Charles (IM) injection into the ischemic area or can be systemi-River Laboratories (Barcelona, Spain) and FVB-TgN cally distributed by intravenous (IV) administration.
(Tie2-GFP)287 Sato (24) mice were purchased from Both methods have proved to be effective (17, 29) , but Jackson Laboratories (Bar Harbor, ME). Animals were few studies have directly compared the effects of either housed in a conventional clean facility for at least a approach within the same experiment (15) , and none in week before experimental use, and given ad libitum acthe hindlimb ischemia setting. cess to mouse chow and tap water. Donor and recipient Most importantly, irrespective of the cell source or mice were between 6 and 8 weeks of age (16-22 g) at route of administration, a further topic of interest is the the time of study. understanding of the mechanisms involved in the therapeutic effect of the administered cells. In this regard, Bone Marrow Harvest and Cell Selection some of the studies from animal models have shown that donor BM cells may "transdifferentiate" into host tissue Donor Tie2-GFP mice were anesthetized and sacrificed by cervical dislocation. Tibiae, femurs, iliac bones, cells and remain in the corresponding damaged organ (the contribution of donor-derived EPC to neovasculari-and vertebrae were removed and cleaned. BM cells were obtained using the optimized method described by Col-zation may range from 5% to 25%) (10,25). However, other studies have shown that only a very small propor-vin et al. (9), crushing the bones in a mortar with a pestle using cold PBS. Marrow cells were then filtered tion of cells, if any, transdifferentiate into endothelial cells, suggesting that most of the beneficial effects are through a 40-µm strainer and washed once. MNC were obtained after gradient density centrifugation with Fi-mediated by paracrine-secreted factors (26, 36, 39) , supporting that cytokine or growth factor administration coll-Paque (GE Healthcare Bio-Sciences, AB, Uppsala, Sweden). For prominin-1 and CD11b selection, we em-could be an alternative or an adjuvant to cellular therapy (22) . ployed the respective selection kits from Miltenyi Biotec (Bergisch Gladbach, Germany), strictly following the The availability of cell-tracking systems may shed some light on the discussion of the mechanism of action manufacturer's instructions. Briefly, MNC were incubated for 15 min at 4°C with FcR blocking reagent and of the transplanted cells (19) . In this regard, the Tie2-GFP transgenic model initially described by Motoike et anti-mouse CD133 monoclonal antibody. Labeled cells were loaded on a manual magnetic separation column al. (24) is valuable. In this model, GFP expression in transgenic mice is controlled by the Tie2 promoter, a device (VarioMACS, Miltenyi Biotec). Purity of the selected populations (both prominin-1 and CD11b) was as-well-known endothelial marker activated during angiogenesis (32) . If several stem cell subsets from the BM sessed by flow cytometry by anti-mouse CD133 conjugated with phycoerythrin (PE) and anti-CD11b conjugated of transgenic mice are transplanted into ischemic areas of wild-type animals, they will only become GFP posi-with allophycocyanin (APC), respectively, both from Miltenyi Biotec. Purity was >95% in both cases. tive if they express Tie2. If this is accompanied by their 
Induction of Hindlimb Ischemia
struments, Axminster, Devon, UK) in the left femoral artery surface area. A median number of 15 measures Hindlimb ischemia was induced by ligation of the left were performed at each time point per animal. Basal iliac artery as described by Peñuelas et al. (28) . Wildblood flow was determined in the same way in 25 recipitype FVB mice were anesthetized with IP administration ent mice before surgery. of ketamin (75 mg/kg) and xylazin (10 mg/kg) and subjected to surgery under sterile conditions. A laparotomy Capillary Density in Ischemic Muscles and GFP + was performed and the iliac arteries were localized at Cell Detection the bifurcation of the abdominal aorta. The left iliac ar-On days 7, 14, and 21 after cell administration, detery was then ligated proximally to the bifurcation and pending on the experimental group, mice were deeply distally close to the inguinal ligament with 7/0 nylon anesthetized with ketamin and xylazin and perfused inligatures. All animals received an anti-inflammatory tra-aortically with 0.9% saline followed by a fixative soagent (ketoprofen, 5 mg/kg subcutaneously) daily for 3 lution containing 4% paraformaldehyde and 0.2% picric days and an antibiotic (enrofloxacin, 25 mg/kg, in drinkacid in phosphate buffer. The ischemic muscles (adducing water) for 5 days after surgery. Between 7 and 10 tors) were dissected and postfixed in the same solution ischemic mice were employed for each experimental for 4 h, then washed and cryoprotected in 30% sucrose group described in Figure 1 (CD133 IV, CD133 IM, buffer and finally embedded in optimal cutting tempera-CD11b IV, CD11b IM, vehicle-injected IV, vehicle-injected ture (OCT) compound (Sakura Finetek Europe, Zoeter-IM, conditioned medium-injected IV, and conditioned woude, The Netherlands) and frozen at −20°C. For all medium-injected IM) and for each time point evaluated staining and analysis, 6-µm-thick sections were obtained (7, 14, and 21 days after the induction of ischemia).
in a Leica CM2000 cryostat (Leica Microsystems, Nus-Cell Administration sloch, Germany). Slides were incubated with a primary Twenty-four hours after left iliac artery ligation, 1 × rabbit polyclonal anti-eNOS antibody (Santa Cruz Bio-10 6 CD133 + selected cells or 1 × 10 6 CD11b selected technology, Santa Cruz, CA) and with a mouse monocells, depending on the experimental group ( Fig. 1) , clonal anti-GFP antibody (Abcam, Cambridge, UK) to were administered either IV or IM. For the IV injection, amplify the GFP signal, diluted in PBS containing 5% cells were diluted in a final volume of 200 µl and ingoat serum, and 0.2% Triton X-100. After several rinses jected in the tail vein. For IM administration, cells were in PBS, sections were further incubated with a mixture diluted in 30 µl and injected in the left quadriceps. The of Cy3-conjugated goat anti-rabbit IgG and Cy2-conjugroups that received no cells (vehicle-treated mice) regated goat anti-mouse IgG (Jackson Immunoresearch, ceived the aforementioned volumes of PBS, either IV West Grove, PA), diluted in PBS with 0.2% of Triton or IM.
X-100. Sections were then counterstained with 4′,6-diamidino-2-phenylindole (DAPI; Sigma, St. Louis, MO).
BM Conditioned Medium Administration
Finally, sections were washed, mounted, and cover-In order to compare the potential angiogenic effects slipped with the antifading mounting medium Fluoroof cell injection with the effects of in vivo cytokine and mount (Sigma). Slides were analyzed on an Olympus growth factor administration, BM-MNC conditioned Provix AX70 photomicroscope (Olympus, Tokio, Japan) medium was also administered to a subgroup of ischeequipped with epifluorescence and appropriate filter mic mice, and the IV and IM routes were compared. For sets. Images were digitalized by a DP-70 digital camera this purpose, MNC were obtained as indicated before, (Olympus) adapted to the microscope and connected to and seeded at a density of 1 × 10 6 cells/cm 2 in fibroneca computer with the DP manager software (Olympus was used. The capillary density was quantified as the BioWhittaker, Lonza, Verviers, Belgium), and 1% penipercentage of the muscular area formed by blood capilcillin/streptomycin (Gibco, Invitrogen). BM-MNC were laries. Capillaries were identified by the eNOS immunomaintained at 37°C in a humidified atmosphere of 5% fluorescence displayed by endothelial cells. Five eNOS-CO 2 for 48 h. Supernatants were collected, filtered with stained muscular images were randomly taken from each 0.22-µm-pore nylon filters, and administered to ischeslide using the 20× objective. Between 5 and 10 slides mic wild-type FVB mice in the same volumes, using the were analyzed per animal. Those digital images were same procedures as for the cell-treated groups.
treated to balance the signal-to-noise ration so that posi-Blood Flow Assessment tive elements were clearly distinguishable from the background. They were then manually transformed into On days 7, 14, and 21 after cell administration, blood flow (in µl/s) was measured by laser-Doppler (Moor In-binary images where only immunostained elements ap-peared as white pixels. Then, the capillary density was RESULTS calculated as the white/black pixel ratio in the entire im-Blood Flow Recovery age. Within the same analysis, number of GFP + endothe-As it is depicted in Figure 2 , blood flow in the ischelial-compatible cells was determined by direct quantifimic muscles progressively recovered after iliac artery cation of elements displaying green fluorescence in each ligation, even in the control group, although this imanalyzed field. The number of GFP + cells was calculated provement reached a plateau around day 7. Nevertheas the percentage of total endothelial cells (eNOS + ) per less, in all the cell-treated groups (CD133 + IM, CD133 + slide (at least 500 endothelial cells were counted per IV, CD11b + IM, and CD11b + IV) blood flow was signifslide).
icantly higher than in controls at every time evaluated (p < 0.001 in all cases). At day 21, blood flow in all In Vitro Analysis of Endothelial Differentiation treated groups was close to the normal values. When In a different set of experiments, selected CD133 + comparing CD133 + with CD11b + cell administration, cells and CD11b + cells (obtained as indicated before) blood flow recovery was significantly faster at day 7 in from Tie2-GFP mice were cultured in two different stananimals treated with CD133 + cells (183 ± 4 vs. 162 ± 5 dard proangiogenic media (38,45). The first one was the µl/s; p < 0.001), and also at day 14 (210 ± 3 vs. 197 ± 6 endothelial growth medium-2 (EGM-2) Bullet kit (endo-µ/s; p = 0.001), but these differences disappeared at day thelial cell basic medium, hydrocortisone, FGF-b, VEGF, 21 after transplantation ( Fig. 2A) . Regarding the admin-R3-IGF-1, ascorbic acid, EGF, GA-1000, and heparin) istration route, there were no differences in blood flow supplemented with 10% fetal bovine serum (Cambrex, recovery between those mice that received either Walkersville, MD, USA). The second media consisted CD133 + or CD11b + cells with the IM route and those of DMEM (Gibco), 20% FCS (BioWhittaker), 1% peniwho were treated with the IV route ( Fig. 2B ). cillin/streptomycin (Gibco), and 100 µg/ml of endothe-
The administration either via IV or IM of BM condilial cell growth supplement (Sigma). CD133 + cells and tioned medium did not induce any improvement in the CD11b cells were seeded in fibronectin-coated six-well blood flow, as can be observed also in Figure 2 . culture plates at a density of 5 × 10 5 cells/cm 2 
and at
Capillary Density and Detection of GFP + Cells 37°C in a humidified atmosphere of 5% CO 2 . Cells were maintained for 7, 14, and 21 days (depending on the In accordance to what was observed in the blood flow experiment). As controls, CD133 + and CD11b + cells analysis, capillary density decreased promptly after iliac from wild-type FVB mice were equally selected and culartery ligation, but progressively recovered to a maxitured. At the aforementioned times, cells were harvested mum value around 3% of total muscle area ( Fig. 3) . after trypsinization and then washed. Cells were then Capillary density was significantly higher in all cellprocessed for flow cytometric evaluation of GFP exprestreated groups than in controls (p < 0.01 in all cases). sion and were also incubated with anti-mouse CD31 Upon comparing different cell sources, capillary density conjugated with PE (Becton Dickinson Bioscienceswas similar in mice treated with CD133 + cells and those BDB, San Jose, CA). At least 5 × 10 4 events were acreceiving CD11b + cells. Concerning the administration quired in a dual-laser FACSCalibur flow cytometer usroute, we found similar values in the intramuscular and ing the CellQuest software (BDB). The latter, together intravenous groups. with Paint-A-Gate PRO software (BDB), were em-Finally, and in accordance to what was observed in ployed for data analysis, as previously described (31) .
the blood flow analysis, the administration of BM conditioned medium did not improve the capillary density Statistical Analysis compared to the vehicle-injected animals, as also shown in Figure 3 . All statistical analyses were performed with SPSS Together with the eNOs staining that was used for 15.0 software (SPSS Inc., Chicago, IL). For each varicapillary density quantification (see Materials and Methable under study, percentages or means, SEMs, medians, ods section), we also investigated the presence of GFP + and ranges were calculated. For continuous variables, cells in the ischemic muscles analyzed. We could not normality was assessed by the Kolmogorov-Smirnov find any significant number of GFP + eNOS + endothelialtest. When the assumption of normality was met, differlike cells. Therefore, we can estimate that the number of ences between groups were tested by one-way ANOVA Tie2 + cells is lower than 1 in 500 eNOS + cells. with Bonferroni, Scheffe, and Tukey post hoc corrections. Otherwise, the nonparametric Kruskal-Wallis test
In Vitro Proangiogenic Differentiation was performed. Differences between groups were considered to be statistically significant for values of p < In vitro differentiation of both cell types (CD133 + and CD11b + ) from Tie2-GFP mice was tested by cell culture 0.05. with two different proangiogenic media during 7, 14, sion, because fluorescence was absent in the FITC channel (where GFP expression would be detected) (Fig. 4) . and 21 days. We found that, irrespective of the differentiation medium employed, cultures of neither cell type DISCUSSION gained CD31 expression, another classic endothelial marker, throughout the culture. Most importantly, nei-
The present article is, to the best of our knowledge, the first to evaluate in the same experiment the angio-ther CD133 + nor CD11b + activated Tie2 gene expres- genic ability of two cell populations that have already sively composed of monocytes) may be associated with an increase of inflammatory cytokines in the ischemic been employed in clinical trials of hindlimb ischemia and that have been claimed as endothelial progenitor area as well as inflammatory infiltration that may lead to unexpected events (1, 35, 44) , as has also been de-cells (CD133 + and monocytes). In addition, we have also assessed the two routes of cell delivery most widely em-scribed after CD34 + cell administration (4) but not when CD133 + are injected (43) . The fact that we did not ob-ployed (IV and IM) in this setting (2) . Moreover, by using the Tie2-GFP transgenic model, we have also serve a significant inflammatory infiltrate in the ischemic muscles in the CD11b + group (data not shown) may tested whether transdifferentiation of these two BM cell subsets into Tie2 + eNOS + endothelial cells is the main be justified by the absence of lymphocytes and neutrophils within this administered cell subset, as others have mechanism of action of their angiogenic effect. Unlike cell administration, we have also demonstrated that the also noted (2, 4) . With respect to the administration route, it is well IV or IM delivery of BM-MNC conditioned medium has no angiogenic effect.
known that after IV administration, a number of BM cells get trapped in the spleen, liver, or lung microcircu-We have shown that both CD133 + cells and monocytes (CD11b + cells) have a similar ability to improve lation (11, 13) . This may explain why most of the clinical trials of cell therapy for chronic limb ischemia cells use the blood flow and the capillary density of the ischemic muscles in our experimental model, with no differences the IM route (2) . Nevertheless, in our work the IV administration gave similar results to those with IM ad-between the two cell sources with the exception of a faster flow recovery when CD133 + selected cells were ministration. Because the engraftment of the administered cells in the damaged tissue is constantly low in administered. This has also been shown after CD34 + cell administration (a cell subset that, as opposed to CD133 + most of the published experiments (2), the number of cells that home to the ischemic muscles may be similar cells, contains mature endothelial cells) (34) when compared with CD14 + monocytic cells in a different animal in both administration routes, although, unfortunately, the transplant model used in our study, Tie2-GPF FVB model (4) . The clinical implications of a faster improvement when selected hematopoietic stem cell populations donor mice into wild-type FVB, did not allow us to measure the percentage engraftment. (either CD34 + or CD133 + cells) are administered for hindlimb ischemia remain to be determined. It has been Finally, our study shows that neither CD133 + cells nor CD11b + cells from Tie2-GFP FVB mice are able to shown that MNC administration (mostly but not exclu- 
